Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

NCT03346434 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic

Interventions

DRUG: Dupilumab
DRUG: Matching placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]